VEGFA and cancer: Therefore, a synchronized increase in the intratumoral level of CCL9 and the other anti-angiogenic chemokine (or administration of, e.g., anti-VEGF drugs like aflibercept, ranibizumab, bevacizumab) would enable the management of more than one process, leading to cancer progression.